Research:
- Parravani is the author of the images and the subject at the same. She is both the viewer, the viewed, and inserts a large amount of control over the image while also losing control by making herself vulnerable.” Parravani has taught photography at Dartmouth College, Columbia University, and the University of Massachusetts, Amherst.
- Parravani is left alone with two young daughters in West Virginia, where she runs out of grocery money, crawls up and down the stairs of her rented home and hides her struggles from colleagues. Her job as an English professor, the only stable work the family has, is a financial lifeline amid a frightening sea of debt.
Parravani Name Meaning Historically, surnames evolved as a way to sort people into groups - by occupation, place of origin, clan affiliation, patronage, parentage, adoption, and even physical characteristics (like red hair). Many of the modern surnames in the dictionary can be traced back to Britain and Ireland. PARRAVANI Giuseppe Giuseppe Parravani (ca1884 - 1931) was born in Broccostella, Frosinone, Italy in 1883-4. His parents were Agostino Parravani, a carrier, and Maria Concetta Ferri. Giuseppe looked. GUILDERLAND Cara Parravani, writer and teacher, died at her mother's home in Guilderland on June 13, 2006. Cara earned a B.A. In creative writing at Bard College, where she studied Italian.
Investigator-initiated- 2007-2009. Prospective, randomized trial of low dose 4.4% sodium citrate versus standard heparin as a catheter lock solution in patients undergoing hemodialysis with a transcutaneous cuff catheter. Role: Principal-investigator (PI)
Industry Supported: Hoffman-La Roche-2007-2009. Open-label, multi-center, study to document the efficacy, safety, and tolerability of long-term administration of R00503821 in patients with chronic renal anemia. Role: Sub-investigator (Sub-)
Industry Supported: Amgen Pharmaceuticals: 2007-2009. Evaluation of cinacalcet HCL therapy to lower cardio vascular events. Role: Sub-Investigator (Sub-I)
Industry Supported: Affymax Pharmaceuticals: 2008 —2010. Phase 3, randomized, active-controlled, open-label, multi-center, study of the safety and efficacy of AF37702 injection for the correction of anemia in patients with chronic renal failure not on dialysis and not on an erythropoietin stimulating agent. Role: Sub-Investigator (Sub-I)
Industry Supported: Affymax Pharmaceuticals: 2008-2010. Phase 3, randomized, active-controlled, open-label, multi-center, study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin alfa Role: Sub-Investigator (Sub-I)
Dr Anthony Parravani Wvu
Industry Supported: Kurhea Incorporated: 2009-2012. Phase 3, randomized, double-blind, placebo-controlled study of AST-120 for prevention of CKD progression in patients with moderate to severe CKD, including assessment of quality of life. Role: Sub-Investigator (Sub-I)
Industry Supported: Genzyme Incorporated: 2008-2012. Fabry Disease Registry. Role: Sub-Investigator (Sub-I)
Industry Supported: Amgen Pharmaceuticals: 2007-2009. Phase 2, randomized, double-blind, placebo-controlled, parallel group, fixed dose study of AMG223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia Role: Sub-Investigator (Sub-I)
Industry Supported: (DOPPS IV) 2010-2012. Dialysis Outcomes and Practice Patterns Study IV Role: Sub Investigator (Sub-I)
Industry Supported: REATA study 201 1-2012. Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes. Role: Sub-Investigator (Sub-I)
Industry Supported: (DOPPSV) 2013-2015. Dialysis Outcomes and Practice Patterns Study V. Role: Sub-Investigator (Sub-I)
Industry Supported: ABBVIE Protocol Ml 1-352 (SONAR Study) 2013-present Role: Sub-investigator (Sub-I)
Parravani
Grant: Utility of an Integrated Diagnostic Tool for Outcomes in Patients 2014-present With Stages 4 and 5 Chronic Kidney Disease (CKD) Role: Sub-Investigator (Sub-I)
Industry Supported: (DOPPS VI) 2015-present. Dialysis Outcomes and Practice Patterns Study VI Role: Sub-Investigator (Sub-I)
Industry Supported: (CKDOPPS) 2014-present. Chronic Kidney Disease Outcomes and Practice Patterns Study Role: Sub-investigator (Sub-I)
Industry Supported: Otsuka Protocol 156-13-210 (REPRISE Study) 2014-present. Gone with the wind download. Phase 3b, Multi-Center, Randomized-Withdrawal, Placebo-controlled, Double-Blind, Parallel-Group Trial to Compare the Efficacy andSafety of Tolvaptan (45-120mg/day, split dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease. Role: Sub-Investigator (Sub-I)
Industry Supported: Fibrogen (FG-4592 Study) 2015-present. Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the treatment of Anemia in CKD Patients not on Dialysis. Role: Sub-Investigator (Sub-I)
Industry Supported: OTSUKA (Protocol 156-13-211) 2015-present. Phase 3b, Multi-Center, Open-label, Trial to Evaluate the Long term Safety of Titrated Immediate Release Tolvaptan (30-120mg/day, split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease. Role: Sub-Investigator (Sub-I)